HERS SOME NEWS QTRNS salea force is concentrating on the aids market from todays wire...ViroLogic and Innovex Deploy Sales Force to MarketHIV Drug Resistance Test, PhenoSense-tm- HIV
November 15, 1999 01:38 PM
SAN FRANCISCO--(BUSINESS WIRE)--Nov. 15, 1999--ViroLogic, Inc. today announced that the company's new, full-time sales force will begin visiting HIV physicians today in major markets across the U.S. to promote ViroLogic's recently commercialized phenotypic HIV drug susceptibility assay, PhenoSense HIV. The ViroLogic sales team was assembled in conjunction with Innovex Inc., the leading provider of contract salespeople worldwide, and will begin work today in the Northeast, mid-Atlantic region, the Southeast, the Chicago area, and Northern and Southern California.
"ViroLogic's partnership with Innovex represents the next major step in expanding physician and patient access to PhenoSense HIV," noted William D. Young, Chairman and CEO of ViroLogic. "We have built an outstanding, experienced team of sales representatives that will help ensure that PhenoSense HIV is made broadly available to patients and physicians across the country."
Recent advances in the treatment of HIV infection, which include the use of combinations of three or more potent antiretroviral drugs, have substantially prolonged life and delayed progression to AIDS for many HIV-infected individuals. However, recent studies have reported a steady increase in the rates of treatment failure, due in large part to the emergence of drug-resistant HIV. A recent article in the Journal of the American Medical Association indicated that 26% of patients newly infected with HIV are already resistant to one or more anti-HIV therapies.
PhenoSense HIV can help physicians plan the most effective HIV treatment regimen for their patients. The assay directly measures the susceptibility of HIV to each of the currently available antiretroviral drugs, providing highly accurate, reproducible, and individualized drug susceptibility information within 14 days, half the time required for other commercially available phenotypic resistance tests. The substantial advantage in turnaround time, sensitivity, and reproducibility provided by PhenoSense HIV makes phenotypic HIV resistance testing a practical tool for physicians.
"We are pleased to provide ViroLogic with innovative commercial services that will accelerate the success of PhenoSense HIV," said David M. Stack, President and General Manager of Innovex. "We expect the new sales team to flourish and help advance ViroLogic's therapy guidance technology."
ViroLogic, a privately held South San Francisco-based biotechnology company, is a leader in the development of novel therapy guidance tools to enable patients, physicians, and medical reimbursers to make rational treatment decisions in the management of viral diseases and cancer. The company's proprietary technology is also being used in the fields of viral pharmacogenomics to identify, analyze, and select new drug candidates for treating viral diseases and cancer, and in disease management through the development of therapy guidance algorithms to guide patient therapy.
Innovex Inc. is a division of Quintiles Transnational Corp. QTRN , the world's first Contract Pharmaceutical Organization (C.P.O.). Innovex is unique in offering an integration of commercial solutions to pharmaceutical industry customers. The broad array of Innovex services range from late phase clinical research to long-term strategic marketing partnerships. Extensive capabilities in Late Phase Clinical Research, Health Management, and Marketing and Sales Services ideally position Innovex to fulfill the diverse needs of the healthcare industry. As a member of the Quintiles Family of Companies, with more than 65 offices in 23 countries, Innovex is part of the largest healthcare service organization in the world, offering customers contract services from pre-clinical through sales and marketing.
CONTACT: ViroLogic, Inc. Sidney Ho, Director of Public Affairs 650/635-1100, Ext. 206 sho@virologic.com
|
